종양학 영상 AI 시장 동향(2025-2032년) : 규모, 구성 및 성장 동향

The global Oncology Imaging AI market is forecast to grow from US$604.7M in 2023 to US$7.74B by 2032 (32.7% CAGR)-making oncology one of the fastest-scaling categories inside medical imaging AI and a leading indicator for where enterprise buyers will place their next AI budgets.

Overview

Global Oncology Imaging AI Market Pulse 2025-2032: Size, Mix & Momentum is Marketstrat's world-market sizing and forecasting report for AI in cancer imaging-covering how demand is shifting across regions, modalities (CT, mammography/DBT, MRI, PET/Nuclear, ultrasound), clinical applications, tumor sites, care pathway stages, end-use settings, and revenue models.

This Pulse is built for teams who want a clean, quantitative global view-without needing to navigate a full multi-hundred-page Horizon program. It delivers a fast, decision-grade answer to:

• How big is the global oncology imaging AI market today-and where will it be by 2032?
• Where is the mix of spend concentrated (the "big pools")?
• Where will incremental dollars accrue (the "fast pools" and "growth contribution" lanes)?
• How do monetization models shift (software vs services vs cloud/usage-based)?

Market expands from US$604.7M (2023) to US$7.74B (2032) at a 32.7% CAGR, driven primarily by attach-rate expansion and workflow adoption, not scanner unit growth.

Key Market Trends (what's changing)

1. From "point AI" to pathway adoption

Oncology imaging AI is shifting from single-task CAD toward pathway-wide workflows-screening, detection, staging, treatment planning (including RT), response assessment, and surveillance-where standardized measurement becomes a clinical and economic requirement.

2. Screening programs anchor predictable AI volumes

Breast screening (mammography/DBT) and LDCT lung screening continue to expand and industrialize, increasing demand for AI that supports triage, QA, second reads, and program operations at scale.

3. Measurement-grade quantification becomes the value center

Across MRI (prostate/liver), CT (lung pathways), and PET/Nuclear (theranostics), growth increasingly concentrates in quantification, analytics, and structured reporting-tools that make cancer imaging more reproducible and operationally scalable.

4. Premium pools rise in MRI and PET/Nuclear (high ARPU lanes)

MRI is the fastest-growing major modality, and PET/Nuclear grows as a high-value niche as therapy-linked imaging (including theranostics) expands demand for quantification and dosimetry-oriented AI.

5. Monetization shifts toward software + usage + lifecycle services

Software remains the core revenue engine, while cloud/usage-based (PPU) models accelerate in high-volume workflows (screening hubs, teleradiology, and enterprise multi-site networks). Services expand alongside validation, monitoring, and governance requirements.

Competitive Snapshot (commercial reality, not market shares)

This Global Pulse focuses on how the market is captured-not vendor-by-vendor market shares. The report highlights the commercial rails that shape winners and pricing power across segments:

• OEM bundling and "default attach" economics in high-volume modalities and screening lanes
• Enterprise contracting and governance requirements in IDNs and cancer networks
• Marketplace/platform distribution that reduces deployment friction for multi-vendor portfolios
• Teleradiology and centralized reading hubs as catalysts for usage-based pricing and standardized QA

The following companies/divisions have been mentioned (not profiled): Aidoc; AIQ Solutions; Annalise.ai; Arterys; Bayer; Blackford; Calantic; Canon Medical; CARPL.ai; DeepHealth; Deepwise; Densitas; EXINI Diagnostics; Fujifilm; GE HealthCare; Hermes Medical Solutions; Hologic; Imbio; Incepto; Kheiron; Koios Medical; Lantheus; Lunit; Median Technologies; MIM Software; Mindray; Mirada Medical; MVision AI; Nuance; Oxipit; Perspectum; Philips; Ping An Healthcare; Quibim; Qure.ai; Rad AI; RadNet; RaySearch; Riverain; ScreenPoint; Sectra; Segami; Siemens Healthineers; Subtle Medical; Tempus; TheraPanacea; United Imaging; Vara; Varian

Sample Insights & Figures (what you'll be able to cite)

Inside this report, readers gain immediate answers to questions such as:

• Which regions are over- or under-indexed in specific modalities or pathway stages versus the global mix?
• Where is the largest dollar lift coming from-by modality, tumor site, pathway stage, and revenue stream?
• Which tumor-site x modality combinations create the most incremental dollars (e.g., breast x X-ray/DR, lung x CT, prostate x MRI)?
• Where are cloud/PPU models structurally advantaged versus traditional licensing?

This Pulse includes 41 figures and 36 tables, structured to be reusable in planning decks, investment briefs, and GTM prioritization.

What's Inside

• Executive Summary focused on global size, growth, and the few mix shifts that matter most
• Condensed Research Methodology (scope definition, segmentation compass, and forecast architecture)
• World Market Analysis (2023-2032) across:
  • Region and selected country views
  • Modality mix and growth contribution
  • Clinical application mix and momentum
  • Tumor-site mix and growth contribution
  • Revenue streams (hardware, software, services, cloud/PPU)
  • End-use organizations (IDNs/AMCs, cancer centers, community providers, teleradiology)
  • Pathway stage dynamics (screening -> treatment planning/RT -> response/surveillance)
  • Mix & Momentum matrices and cross-tabs (e.g., region x modality, tumor site x modality, pathway stage x revenue stream)

Why This Report

Global Oncology Imaging AI Market Pulse 2025-2032 is built for teams that need high-confidence sizing plus practical segmentation-the combination required to make real decisions:

• Portfolio and roadmap decisions: Which modalities and tumor sites are worth sustained investment?
• Market entry and sequencing: Where do you start (big pools) vs where do you place selective bets (fast pools)?
• Commercial strategy: How will revenue models evolve (license vs service vs usage), and where will pricing compress vs hold?
• Investor and diligence workflows: Which growth narratives are supported by global mix/momentum patterns rather than anecdote?

TABLE OF CONTENTS

SECTION 0 - HOW TO USE THIS GLOBAL MARKET PULSE

SECTION 1 - GOBAL MARKET SNAPSHOT (2023-2032)

SECTION 2 - EXECUTIVE SUMMARY

SECTION 3 - RESEARCH METHODOLOGY

SECTION 4 - WORLD MARKET FOR ONCOLOGY IMAGING AI

• 4.1 WORLD MARKET OVERVIEW
  • Oncology Imaging AI: From Niche App to Enterprise Platform
    • Why Adoption is Accelerating
  • Regional Growth Snapshot (2023 -> 2032)
  • Strategic Implications for Vendors
  • Market Momentum & Outlook
• 4.2 WORLD MARKET FORECAST BY REGION (2023-2032)
• 4.3 WORLD MARKET BY COUNTRY x END-USE ORG
  • Estimate by Country x End-Use (USD Mill, 2023)
  • Forecast by Country x End-Use (2032)
  • Highlights (2032 Country Pattern vs World Mix)
  • What's Shifting vs 2023 (Directional)
  • Top Growth Cells (US$ M Lift, 2023->2032)
  • What This Means (Commercial Playbook)
  • Signals to Watch
• 4.4 WORLD MARKET BY MODALITY
  • Highlights
  • World Market by Modality (2023-32)
    • Implications
  • Market Math & Diffusion Pattern
    • 2032 Mix and Key Growth Lenses
    • Share Shift and Dollar Lift (2023 -> 2032)
  • Competitive Landscape - by Modality
  • Modality Deep-Dives (Oncology-specific)
    • CT
    • X-ray/DR (incl. Mammography)
    • MRI
    • PET/Nuclear
    • Ultrasound
  • Strategic Takeaways for Vendors (Oncology-specific)
  • Signals to Watch (2025-2027)
• 4.5 WORLD MARKET BY CLINICAL APPLICATION
  • Highlights
  • World Market by Clinical Application (2023-32)
  • What's Shifting
  • Key Growth Lenses by Application
  • Who Contributes the Growth (2023->2032 lift)
  • What This Means
  • Competitive Landscape - by Clinical Application
  • Deep Dives by Clinical Application
    • Detection & Diagnosis
    • Quantification & Analytics
    • Workflow & Orchestration
    • Reporting & Communication
    • Image Reconstruction & Acquisition
  • Strategic Takeaways for Vendors
  • Signals to Watch (2025-2027)
    • 4.6 WORLD MARKET BY TUMOR SITE
  • Highlights
  • What's Shifting (Mix Dynamics)
  • World Market by Tumor Site (2023-32)
  • Growth Lenses - by Tumor Site
  • What This Means
  • What Shifts Through 2032
  • Commercial Takeaways
  • Competitive Landscape - by Tumor Site
  • Deep Dives by Tumor Site
    • Breast
    • Lung/Chest
    • Prostate
    • Colorectal
    • Liver
    • Neuro-Oncology
    • Gynecologic
    • Head & Neck
    • Other (Rare)
  • Strategic Takeaways
  • Signals to Watch (2025-2027)
• 4.7 WORLD MARKET BY REVENUE STREAM
  • Highlights
  • What's Shifting
  • World Market by Revenue Stream (2023-32)
  • Growth Lenses - by Revenue Stream
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What This Means
  • Deep Dives by Revenue Stream
    • Hardware
    • Software
    • Service
    • Cloud/PPU
  • Competitive Landscape - by Revenue Stream
  • Signals to Watch (2025-2027)
• 4.8 WORLD MARKET BY END-USE ORGANIZATION TYPE
  • Highlights
  • What's Shifting
  • World Market by End-Use Organization (2023-32)
  • Growth Lenses by End-use
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What this Means
  • Deep Dives
    • Academic/IDNs
    • Comprehensive Cancer Centers
    • Community Hospitals & Imaging Centers
    • Teleradiology Providers
  • Competitive Landscape - by End-Use
  • Signals to Watch (2025-2027)
• 4.9 WORLD MARKET BY AI TECHNOLOGY
  • Highlights
  • What's Shifting
  • World Market by AI Technology (2023-32)
  • Growth Lenses - by AI Technology
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What This Means
  • Deep Dives by AI Technology (Oncology Lens)
  • Competitive Landscape - by AI Technology
  • Signals to Watch (2025-2027)
• 4.10 WORLD MARKET BY PATHWAY STAGE
  • Highlights
  • What's Shifting
  • World Market by Pathway Stage (2023-32)
  • Growth Lenses - by Pathway Stage
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What This Means
  • Competitive Landscape - by Pathway Stage
  • Signals to Watch (2025-2027)
• HOW TO INTERPRET "MIX & MOMENTUM" MATRICES
• 4.11 REGIONAL MIX & MOMENTUM - WORLD ONCOLOGY IMAGING AI
  • Executive Takeaways
  • Marke by Region x Modality
    • World Market by Region x Modality - 2023
    • World Market by Region x Modality - 2032
    • What's Shifting (Mix, 2032 Over/Under-index)
    • Who Contributes the Growth (2023->2032 Lift)
    • What This Means
  • Market by Region x Revenue Stream
    • World Market by Region x Revenue Stream - 2023
    • World Market by Region x Revenue Stream - 2032
    • What's Shifting (Mix, 2032 Over/Under Index)
    • Who Contributes the Growth
    • What This Means
  • Market by Region x Clinical Application
    • World Market by Region x Clinical Application - 2023
    • World Market by Region x Clinical Application - 2032
    • What's Shifting (Mix, 2032 Over/Under Index)
    • Who Contributes the Growth
    • What this Means
    • Competitive Snapshots (Illustrative)
• 4.12 DISEASE-DRIVEN DEMAND MAP - WORLD ONCOLOGY IMAGING AI
  • Executive Takeaways
  • Tumor Site x Modality
    • World Market by Tumor Site x Modality - 2023
    • World Market by Tumor Site x Modality - 2032
    • What's Shifting (2032 Mix vs Global)
    • Who Contributes the Growth (2023->2032 Dollar Lift)
    • What This Means
  • Tumor Site x Clinical Application
    • World Market by Tumor Site x Clinical Application - 2023
    • What's Shifting (2032 Mix vs Global)
    • World Market by Tumor Site x Clinical Application - 2032
    • Who Contributes the Growth (2023->2032 Dollar Lift)
    • What this means
  • Tumor Site x Revenue Stream
    • World Market by Tumor Site x Revenue Stream - 2023
    • World Market by Tumor Site x Revenue Stream - 2032
    • What's Shifting (2032 mix vs global)
    • Who Contributes the Growth (2023->2032 Dollar lift)
    • What This Means
  • Competitive Snapshot (Illustrative, Oncology-focused)
  • Signals to Watch
• 4.13 WORKFLOW ECONOMICS - WORLD ONCOLOGY IMAGING AI
  • Modality x Revenue Stream
    • World Market by Modality x Revenue Stream - 2023
    • World Market by Modality x Revenue Stream - 20232
    • Highlights
    • What's Shifting (Mix & Over/Under-Index)
    • Who Contributes the Growth (2023->2032 Dollar Lift)
    • What This Means (Commercial Playbook)
    • Competitive Lens (Illustrative)
  • Clinical Application x Revenue Stream
    • Highlights (2032 Pattern)
    • World Market by Clinical Application x Revenue Stream - 2023
    • World Market by Clinical Application x Revenue Stream - 2032
    • What's Shifting (2023 -> 2032)
    • Who Contributes the Growth (US$ M lift, 2023->2032)
    • What This Means (Commercial Playbook by Application)
    • Competitive Lens (Indicative, Non-exhaustive)
    • Pricing Archetypes That Clear Approvals (What Buyers Say "Yes" to)
    • Signals to Watch
    • Risks & Watchouts
• 4.14 PATHWAY STAGE ECONOMICS - WORLD ONCOLOGY IMAGING AI
  • Pathway Stage x Revenue Stream
    • Highlights
    • World Market by Pathway Stage x Revenue Stream - 2023
    • World Market by Pathway Stage x Revenue Stream - 2032
    • What's Shifting (Mix vs Global)
    • Who Contributes the Growth (2023 -> 2032 Dollar Lift)
    • What This Means (Commercial Playbook)
    • Competitive Lens (Indicative)
    • Signals to Watch
  • Pathway Stage x Modality - Where Each Stage Leans and Why
    • World Market by Pathway Stage x Modality - 2023
    • World Market by Pathway Stage x Modality - 2032
    • Highlights (2032 Pattern vs World Mix)
    • Where the Dollars Moved (2023 -> 2032)
    • Stage-specific Readouts (2032 Shares Inside Each Stage)
    • What This Means (Commercial Takeaways)
    • Competitive Lens (Illustrative, not Exhaustive)
    • Signals to Watch
  • Pathway Stage x Clinical Application - How Workloads Drive Spend
    • World Market by Pathway Stage x Clinical Application - 2023
    • World Market by Pathway Stage x Clinical Application - 2032
    • Highlights (2032 Pattern vs World Mix)
    • Where the Dollars Moved (2023 -> 2032)
    • What This Means (Commercial Playbook)
    • Competitive Lens (Indicative)
    • Signals to Watch
  • Pathway Stage x End-use - Who Buys What, and Where Growth Concentrates
    • World Context (2032 End-use Mix)
    • World Market by Pathway Stage x End-use - 2023
    • World Market by Pathway Stage x End-use - 2032
    • Highlights (2032 Pattern vs Global Mix)
    • Who Contributes the Growth (US$ M lift 2023->2032)
    • What This Means (Commercial Playbook by Stage)
    • Competitive Lens (Indicative, Non-exhaustive)
    • Signals to Watch
  • Pathway Stage x AI Technology - How Capability Mix Shifts Across the Cancer Pathway
    • World Tech Mix
    • World Market for Pathway Stage x AI Technology - 2023
    • World Market for Pathway Stage x AI Technology - 2032
    • Highlights (2032 Pattern vs Global Mix)
    • Where the Dollars Moved (2023 -> 2032)
    • What This Means (Commercial Playbook)
    • Competitive Lens (indicative)
    • Signals to Watch